The impact of heparin therapy in deceased donors on early graft survival of kidney and liver recipients: A clinical trial study
The impact of heparin therapy in deceased donors on early graft survival of kidney and liver recipients: A clinical trial study This study aimed to compare the effect of heparin therapy as a therapeutic dose after brain death confirmation on early graft survival of kidney and liver recipients. A total of 71 brain death donors and matched kidney and liver transplants were included in the case group. 43 brain death donors and matched kidney and matched liver transplants were included in the control group.
_crop.png)
The impact of heparin therapy in deceased donors on early graft survival of kidney and liver recipients: A clinical trial study
Marzieh latifi1, Elahe Pourhosein 2, Habib Rahban3, Mohammadreza Khajavi4, Sanaz Dehghani5*
Abstract
Background: Significant hemodynamic, hormonal, and metabolic impairment of a brain-dead organ donor is often associated with the deterioration of graft viability. This study aimed to compare the effect of heparin therapy as a therapeutic dose after brain death confirmation on early graft survival of kidney and liver recipients.
Method and material: The deceased donors were sorted into two groups based on their D-Dimer level. After confirming brain death, one group was given a heparin injection (case group), while the other group did not receive any heparin (control group).
A total of 71 brain death donors and matched kidney and liver transplants were included in the case group. 43 brain death donors and matched kidney and matched liver transplants were included in the control group. 5000 units of heparin every 6 hours were administered to the deceased donor case group.
Results: The mean age of the case and control groups were 36.27 ± 16.13 and 36.15 ± 18.45, respectively. The independentttest showed that there are no differences between the number of procured organs in both groups (P= 0.29).
There was no significant difference between graft survival rate and the doses of heparin injection in liver recipients (P= 0.06). However, it also revealed a significant difference between graft survival rate and the dose of heparin injection (P= 0.004) in kidney recipients.
Conclusion: The data suggest that administering low therapeutic dose heparin to donors before organ donation may potentially prevent thrombosis and provide a protective benefit. We showed that heparin therapy has no significant effect on the number of donated organs and graft survival.
Key words: Brain death, Heparin, Transplantation, Kidney, Liver
ارسال نظر